ATE297207T1 - 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten - Google Patents

4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten

Info

Publication number: ATE297207T1
Authority: AT; Austria
Prior art keywords: subtype; piperidine; benzyl; receptor antagonists; nmda receptor
Prior art date: 1998-06-26

Application number

AT99931887T

Other languages

English (en)

Inventor

Jonathan L Wright

Suzanne Ross Kesten

Ravindra B Upasani

Nancy C Lan

Original Assignee

Warner Lambert Co

Cocensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-26

Filing date

1999-06-25

Publication date

2005-06-15

1999-06-25 Application filed by Warner Lambert Co, Cocensys Inc filed Critical Warner Lambert Co

2005-06-15 Application granted granted Critical

2005-06-15 Publication of ATE297207T1 publication Critical patent/ATE297207T1/de

Links

229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT99931887T 1998-06-26 1999-06-25 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten ATE297207T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9091498P	1998-06-26	1998-06-26
PCT/US1999/014291 WO2000000197A1 (en)	1998-06-26	1999-06-25	4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE297207T1 true ATE297207T1 (de)	2005-06-15

Family

ID=22224939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99931887T ATE297207T1 (de)	1998-06-26	1999-06-25	4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten

Country Status (28)

Country	Link
US (1)	US6284774B1 (de)
EP (1)	EP1089735B1 (de)
JP (1)	JP2002519322A (de)
KR (1)	KR20010053170A (de)
CN (1)	CN1304307A (de)
AP (1)	AP2000001949A0 (de)
AT (1)	ATE297207T1 (de)
AU (1)	AU769650B2 (de)
BG (1)	BG105082A (de)
BR (1)	BR9911575A (de)
CA (1)	CA2327888A1 (de)
DE (1)	DE69925730T2 (de)
EA (1)	EA200100058A1 (de)
EE (1)	EE200000778A (de)
ES (1)	ES2244201T3 (de)
HU (1)	HUP0102471A2 (de)
ID (1)	ID28005A (de)
IL (1)	IL138949A0 (de)
IS (1)	IS5667A (de)
NO (1)	NO20006482L (de)
NZ (1)	NZ508808A (de)
OA (1)	OA11570A (de)
PE (1)	PE20000728A1 (de)
PL (1)	PL345024A1 (de)
SK (1)	SK19512000A3 (de)
TR (1)	TR200003888T2 (de)
WO (1)	WO2000000197A1 (de)
ZA (1)	ZA200005848B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476041B1 (en) *	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) *	1999-11-01	2005-09-15		Diarylenines
OA12253A (en) *	2000-04-26	2006-05-11	Warner Lambert Co	Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
CA2410660A1 (en) *	2000-06-01	2001-12-06	Warner-Lambert Company	Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
AU2001269540A1 (en)	2000-07-18	2002-01-30	Sumitomo Pharmaceuticals Co. Ltd.	Serotonin reuptake inhibitors
IL145584A0 (en)	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment
HU227197B1 (en)	2000-10-24	2010-10-28	Richter Gedeon Nyrt	Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EA005974B1 (ru)	2001-02-23	2005-08-25	Мерк Энд Ко., Инк.	N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
JP2005506292A (ja) *	2001-03-08	2005-03-03	エモリー　ユニバーシティ	ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
CA2443108A1 (en)	2001-04-03	2002-10-17	Merck & Co. Inc.	N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2381630A1 (en) *	2001-04-23	2002-10-23	Leonard Theodore Meltzer	Method for preventing dyskinesias
DE60228969D1 (de)	2001-07-24	2008-10-30	Richter Gedeon Nyrt
US20030211040A1 (en)	2001-08-31	2003-11-13	Paul Greengard	Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
ES2351303T3 (es) *	2001-12-11	2011-02-02	University Of Virginia Patent Foundation	Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006058236A2 (en)	2004-11-24	2006-06-01	Neuromolecular Pharmaceuticals, Inc.	Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EP2425845A1 (de) *	2004-12-23	2012-03-07	Voyager Pharmaceutical Corporation	Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit
ES2334061T3 (es) *	2005-08-15	2010-03-04	University Of Virginia Patent Foundation	Neurorrestauracion con pramipexol r(+).
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
PL2026803T3 (pl)	2006-05-16	2012-05-31	Knopp Neurosciences Inc	Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de)	2006-11-30	2012-04-18	Probiodrug AG	Neue inhibitoren von glutaminylcyclase
US8524695B2 (en)	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
EP2137171A4 (de)	2007-03-14	2010-05-19	Knopp Neurosciences Inc	Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
CN103497114A (zh)	2007-06-29	2014-01-08	埃莫里大学	用于神经保护的nmda受体拮抗剂
DE102007047737A1 (de)	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
TWI410420B (zh)	2008-02-05	2013-10-01	Dainippon Sumitomo Pharma Co	苄基哌啶化合物
BRPI0910575A2 (pt) *	2008-04-18	2017-06-06	Arizona Board Of Regents A Body Corp Of The State Of Arizona Acting For And Behalf Of The Univ Of Ar	métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
US20110190356A1 (en)	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
HUP0900130A3 (en)	2009-03-03	2012-02-28	Richter Gedeon Nyrt	Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
AU2010279963A1 (en)	2009-08-04	2012-02-23	Dainippon Sumitomo Pharma Co., Ltd.	Benzyl piperidine compound
SG10201507362TA (en)	2009-08-05	2015-10-29	Intra Cellular Therapies Inc	Novel Regulatory Proteins And Inhibitors
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
US8741343B2 (en)	2009-12-02	2014-06-03	Adamas Pharmaceuticals, Inc.	Method of administering amantadine prior to a sleep period
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (de)	2010-04-21	2016-01-06	Probiodrug AG	Hemmer der glutaminylzyklase
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6411215B2 (ja)	2011-11-22	2018-10-24	ザリージェンツオブザユニバーシティオブカリフォルニア	虚血傷害を治療するためのシステアミンおよび／またはシスタミン
US9512096B2 (en)	2011-12-22	2016-12-06	Knopp Biosciences, LLP	Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
HRP20251187T1 (hr)	2013-07-12	2025-11-21	Areteia Therapeutics, Inc.	Liječenje povišenih razina eozinofila i/ili bazofila
US9642840B2 (en)	2013-08-13	2017-05-09	Knopp Biosciences, Llc	Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9763918B2 (en)	2013-08-13	2017-09-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
US10752588B2 (en)	2014-12-19	2020-08-25	The Broad Institute, Inc.	Dopamine D2 receptor ligands
US10633336B2 (en)	2014-12-19	2020-04-28	The Broad Institute, Inc.	Dopamine D2 receptor ligands
MX2020002078A (es)	2017-08-24	2020-09-21	Adamas Pharma Llc	Composiciones de amantadina, preparaciones de estas y métodos de uso.
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US12521365B2 (en)	2019-04-26	2026-01-13	Cytosolve, Inc.	Compositions for improving brain health and memory

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792187A (fr) *	1971-12-03	1973-03-30	Sumitomo Chemical Co	Nouveaux derives d'alkylamines
DE2845537A1 (de) *	1978-10-19	1980-04-30	Bayer Ag	Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) *	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en)	1990-11-28	1992-08-05	Sandoz Ltd.	New uses of competitive nmda receptor antagonists
JPH05194505A (ja) *	1991-08-09	1993-08-03	Yoshitomi Pharmaceut Ind Ltd	チオフェン化合物
US5192751A (en)	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) *	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
EP0709384B1 (de)	1994-10-31	1998-12-23	MERCK PATENT GmbH	Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
EP0825984A1 (de) *	1995-04-07	1998-03-04	Novo Nordisk A/S	Neues verfahren
ZA9610741B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
JP2001501628A (ja) *	1996-10-04	2001-02-06	ノボノルディスクアクティーゼルスカブ	Ｎ―置換化アザ複素環式化合物
DE19643790A1 (de)	1996-10-30	1998-05-07	Merck Patent Gmbh	Benzoxazol-Derivat

1999
- 1999-06-24 PE PE1999000567A patent/PE20000728A1/es not_active Application Discontinuation
- 1999-06-25 US US09/674,298 patent/US6284774B1/en not_active Expired - Fee Related
- 1999-06-25 ES ES99931887T patent/ES2244201T3/es not_active Expired - Lifetime
- 1999-06-25 BR BR9911575-1A patent/BR9911575A/pt not_active Application Discontinuation
- 1999-06-25 AP APAP/P/2000/001949A patent/AP2000001949A0/en unknown
- 1999-06-25 JP JP2000556782A patent/JP2002519322A/ja active Pending
- 1999-06-25 SK SK1951-2000A patent/SK19512000A3/sk unknown
- 1999-06-25 TR TR2000/03888T patent/TR200003888T2/xx unknown
- 1999-06-25 ID IDW20002514A patent/ID28005A/id unknown
- 1999-06-25 PL PL99345024A patent/PL345024A1/xx unknown
- 1999-06-25 EA EA200100058A patent/EA200100058A1/ru unknown
- 1999-06-25 EE EEP200000778A patent/EE200000778A/xx unknown
- 1999-06-25 NZ NZ508808A patent/NZ508808A/xx unknown
- 1999-06-25 AT AT99931887T patent/ATE297207T1/de not_active IP Right Cessation
- 1999-06-25 OA OA1200000347A patent/OA11570A/en unknown
- 1999-06-25 CA CA002327888A patent/CA2327888A1/en not_active Abandoned
- 1999-06-25 IL IL13894999A patent/IL138949A0/xx unknown
- 1999-06-25 DE DE69925730T patent/DE69925730T2/de not_active Expired - Fee Related
- 1999-06-25 CN CN99807087A patent/CN1304307A/zh active Pending
- 1999-06-25 WO PCT/US1999/014291 patent/WO2000000197A1/en not_active Ceased
- 1999-06-25 AU AU48303/99A patent/AU769650B2/en not_active Ceased
- 1999-06-25 HU HU0102471A patent/HUP0102471A2/hu unknown
- 1999-06-25 KR KR1020007014745A patent/KR20010053170A/ko not_active Withdrawn
- 1999-06-25 EP EP99931887A patent/EP1089735B1/de not_active Expired - Lifetime
2000
- 2000-10-16 IS IS5667A patent/IS5667A/is unknown
- 2000-10-19 ZA ZA200005848A patent/ZA200005848B/en unknown
- 2000-12-19 NO NO20006482A patent/NO20006482L/no not_active Application Discontinuation
- 2000-12-21 BG BG105082A patent/BG105082A/xx unknown

Also Published As

Publication number	Publication date
IL138949A0 (en)	2001-11-25
EE200000778A (et)	2002-04-15
AU769650B2 (en)	2004-01-29
OA11570A (en)	2004-07-01
NO20006482D0 (no)	2000-12-19
BG105082A (en)	2001-09-28
ZA200005848B (en)	2001-12-18
BR9911575A (pt)	2001-03-20
HUP0102471A2 (hu)	2002-05-29
US6284774B1 (en)	2001-09-04
PL345024A1 (en)	2001-11-19
ES2244201T3 (es)	2005-12-01
NO20006482L (no)	2000-12-19
AP2000001949A0 (en)	2000-12-31
EP1089735A4 (de)	2002-12-18
DE69925730D1 (de)	2005-07-14
EA200100058A1 (ru)	2001-08-27
PE20000728A1 (es)	2000-08-21
IS5667A (is)	2000-10-16
EP1089735A1 (de)	2001-04-11
DE69925730T2 (de)	2006-03-23
CN1304307A (zh)	2001-07-18
NZ508808A (en)	2002-12-20
JP2002519322A (ja)	2002-07-02
EP1089735B1 (de)	2005-06-08
SK19512000A3 (sk)	2001-08-06
TR200003888T2 (tr)	2001-06-21
WO2000000197A1 (en)	2000-01-06
ID28005A (id)	2001-05-03
AU4830399A (en)	2000-01-17
KR20010053170A (ko)	2001-06-25
CA2327888A1 (en)	2000-01-06

Legal Events

Date	Code	Title	Description
2005-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE297207T1 (de)	2005-06-15	4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60015296D1 (de)	2004-12-02	Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE60106607D1 (de)	2004-11-25	Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE279396T1 (de)	2004-10-15	Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
ATE261945T1 (de)	2004-04-15	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE250039T1 (de)	2003-10-15	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DK1009732T3 (da)	2003-09-22	1-Amino-alkylcyclohexan NMDA receptor antagonister
DE69812096D1 (de)	2003-04-17	Neuropeptid y rezeptorantagonisten
ATE496032T1 (de)	2011-02-15	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE69531458D1 (de)	2003-09-11	Chinolinderivate als tachykinin nk3 rezeptor antagonisten
DE69728392D1 (de)	2004-05-06	Indolderivate verwendbar als endothelinrezeptorantagonisten
ID19623A (id)	1998-07-23	Antagonis reseptor vitronektin
DE69921351D1 (de)	2004-11-25	4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE60114413D1 (de)	2005-12-01	Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE59914921D1 (de)	2009-01-15	1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4-benzylpiperidine als nmda-rezeptor-antagonisten
ID24726A (id)	2000-08-03	Antagonis-antagonis reseptor trombin
DE69919171D1 (de)	2004-09-09	Muskarin-rezeptor antagonisten
ID26223A (id)	2000-12-07	Antagonis reseptor vitronektin
ID24162A (id)	2000-07-13	Antagonis-antagonis reseptor vitronektin
DE50008020D1 (de)	2004-11-04	Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
ATE353881T1 (de)	2007-03-15	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ID28811A (id)	2001-07-05	Antagonis reseptor vitronektin
ATE196766T1 (de)	2000-10-15	Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
DE69408674D1 (de)	1998-04-02	Phenylpyrrol-derivate und ihre verwendung als dopamin d3 antagonisten
ATE228514T1 (de)	2002-12-15	Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten